Explore the vast range of titles available.

High-degree atrioventricular block (HAVB) is a frequent complication in the acute stages of a myocardial infarction associated with an increased rate of mortality. However, the incidence and clinical significance of HAVB in late convalescent phases of an AMI is largely unknown. The aim of this study was to assess the incidence and prognostic value of late HAVB documented by continuous electrocardiogram (ECG) monitoring in post-AMI patients with reduced left ventricular function. The study included 286 patients from the CARISMA study with AMI and left ventricular ejection fraction of 40% or less. An insertable loop recorder was implanted 5 to 21 days after AMI for incessant arrhythmia surveillance. Furthermore, ECG documentation was supplemented by a 24-hour Holter monitoring conducted at week 6 post-AMI. The clinical significance of HAVB occurring more than 21 days after AMI was examined with respect to development of major heart failure events and major ventricular tachyarrhythmic events. During a median follow-up of 1.9 years (interquartile range 0.9-2.0), late HAVB was documented in 30 patients. The risk of major heart failure events (hazard ratio [HR] 4.08 [1.38-12.09], P = .01) and major ventricular tachyarrhythmic events (HR = 5.41 [1.88-15.58], P = .002) were significantly increased in patients who developed late HAVB. High-degree atrioventricular block documented by continuous ECG monitoring occurring more than 3 weeks after AMI is a frequent complication in post-AMI patients with left ventricular dysfunction. Furthermore, HAVB is associated with ominous prognostic implications of both potentially lethal arrhythmias and heart failure.

Aromatase is the last enzyme in estrogenesis, and as such is of central importance in estrogen metabolic and reproductive processes. Four central postulates of aromatase active site topology were elaborated: 1. The C-19 cavity postulate predicted that a cavity exists in aromatase. Steroids synthesized to investigate this postulate have confirmed that a 6A deep pocket exists to accommodate C-19 androgen derivatives. 2. The C-3 chelation postulate suggested that chelating groups at the C-3 position might constitute a new generation of aromatase inhibitors and cause aromatase inactivation. Steroidal derivatives with C-3 ethylenedioxy and C-3 thioketal groups have shown this approach to be invalid. 3. The C-5 nucleophile postulate led to investigate the mechanism of action of known C-4, C-5 and C-6 pharmacophores via C-4,5 and C-5,6 androgen epoxides. No inactivation of the enzyme was reported in the presence of these epoxy-steroids, thus weakening contemporary aromatase mechanistic theory involving mechanisms relying on an incoming C-4 nucleophile. Topological analysis and computer simulations of known pharmacophoric patterns led to the biochemical investigations of over 80 steroidal test compounds, many exhibiting potent competitive and some inactivating kinetic profiles. The synthesis of hitherto unreported androgen derivatives was described. 4. Bioorganic simulations of the aromatase mechanism have led to a novel approach to the aromatase mechanism of action. These approaches are based on altered A-ring reactivity via thioketal or hemi-thioketal enzyme intermediates. The chemistry of postulated active site generated analogues was investigated and the resulting rearrangement products lend credence to mechanisms requiring altered reactivities during aromatase oxidations.

Lyme borreliosis is the most common tick-borne disease in temperate climates of the northern hemisphere. Although in some cases Lyme borreliosis progresses to serious outcomes, no human vaccines are available for its prevention. A previous report showed positive immunogenicity and safety of VLA15, an investigational Lyme borreliosis vaccine based on Borrelia burgdorferi outer surface protein A (OspA), when administered as a 0-2-6-month or 0-6-month primary series to children, adolescents, and adults. Here, we report data from the same trial after receipt of an initial booster dose at month 18. This ongoing, randomised, observer-blind, placebo-controlled, phase 2 trial is taking place at 14 clinical study centres in Lyme borreliosis-endemic areas in the USA. Healthy, eligible participants aged 5–65 years were enrolled. Participants were randomly assigned within each age cohort (18-65 years, 12-17 years, and 5-11 years) in a 1:1:1 ratio to receive intramuscular injections of VLA15 at months 0, 2, and 6; VLA15 at months 0 and 6 and placebo at month 2; or placebo at months 0, 2, and 6. In this phase of the trial, a month 18 VLA15 booster vaccination was administered to participants in both VLA15 groups (termed VLA15 M0-2-6-18 and VLA15 M0-6-18, respectively); the placebo group received placebo at month 18. Data up to month 12, including the primary endpoints, have been reported previously; this report includes data up to month 19. Secondary endpoints related to the month 18 booster vaccination included OspA serotype-specific IgG geometric mean titres (GMTs; evaluated in the per-protocol analysis set) and solicited and unsolicited adverse events (evaluated in the safety analysis set [ie, all participants who received one or more vaccinations]) from month 18 to month 19. This trial is registered at ClinicalTrials.gov, NCT04801420, and is closed for recruitment. Between March 15, 2021, and Feb, 24, 2022, 625 participants were randomly assigned and received the first vaccination. 532 (85%) of 625 participants were White, 68 (11%) were Black or African American, 13 (2%) were Asian, one (<1%) was an American Indian or Alaska Native, and 11 (2%) had their race recorded as other. 321 (51%) of 625 participants were female and 304 (49%) were male. The month 18 booster vaccination was administered to 449 participants at 13 of the trial sites (148 participants in the VLA15 M0-2-6-18 group; 143 participants in the VLA15 M0-6-18 group; 12 other VLA15 recipients; and 146 participants in the placebo group) between Sept 21, 2022, and Jan 24, 2023. The 12 other VLA15 booster recipients, of whom 11 received VLA15 and one received placebo for the month 18 booster, received at least one primary or booster VLA15 dose but could not be evaluated within a designated VLA15 group for safety because of missed or incorrect vaccinations, and were excluded from post-booster immunogenicity analyses. Of the 513 participants included in the per-protocol analysis set, 398 received the booster and 394 completed the month 19 visit. OspA-specific IgG GMTs in both VLA15 groups declined after the primary series up to month 18. At 1 month after the month 18 booster vaccination, GMTs in both VLA15 groups rose to levels that exceeded those after the primary series, ranging in the overall population from 1057·0 U/mL (95% CI 843·1–1325·1; serotype 1) to 1807·9 U/mL (1486·2–2199·3; serotype 2) in the M0-2-6-18 group and from 830·0 U/mL (621·3-1108·9; serotype 1) to 1603·1 U/mL (1239·7–2073·0; serotype 2) in the M0-6-18 group. GMTs at month 19 were higher in the paediatric cohorts compared with adults, consistent with observations after the primary vaccination series. The tolerability profile of the month 18 booster was similar to that of the primary doses and generally similar across age cohorts. Related unsolicited adverse events were reported by four (1%) of 302 VLA15 booster vaccination recipients and three (2%) of 147 placebo booster recipients within 1 month after the month 18 booster; all of these events resolved without sequelae. Unsolicited adverse events leading to trial withdrawal, unsolicited serious adverse events, and adverse events of special interest that were reported up to month 19 were all considered unrelated to trial vaccination and occurred before the month 18 booster. No deaths were reported up to month 19 of the trial. The safety and robust anamnestic immune responses associated with VLA15 boosting support its use as a strategy to increase anti-OspA antibody levels before tick season among children, adolescents, and adults. Forthcoming data after administration of subsequent annual boosters will provide further information about VLA15 antibody persistence and boostability. Valneva and Pfizer.

Background: People living with HIV (PLWH) have been shown to have an increased risk of autoimmune diseases. Corticosteroids are the cornerstone of autoimmune diseases treatment, but their use is associated with an increased risk of infections. It is unclear how HIV status affects the risk of infection associated with corticosteroids use. Methods: We conducted a retrospective cohort study from 1991 to 2011, using a medico-administrative database from Quebec. Medical billing codes were used to identify PLWH, and we matched them on age, sex, and index date with up to 4 HIV-negative controls. The exposure of interest was the use of corticosteroids, defined as a systemic corticosteroid dispensation lasting at least 20 days. The outcome of interest was hospitalization for severe infection. Crude and adjusted incidence rates ratios of infection were obtained using a random effect Poisson model, and results were stratified by HIV status. Results: In total, 4798 PLWH were matched to 17 644 HIV-negative controls, among which 1083 (22.6%) PLWH and 1854 (10.5%) HIV-negative controls received at least one course of corticosteroid. The mean duration of corticosteroids use was 4 ± 4.4 months in PLWH and 1.6 ± 5.5 months in HIV-negative controls. The incidence rate ratio (IRR) for infections associated with corticosteroids use was 2.49[1.71–3.60] in PLWH and 1.32[0.71–2.47] in HIV-negative controls (P value for interaction 0.18). The most frequent infections were pulmonary infections (50.4%), followed by urinary tract infections (26%) and opportunistic infections (10.5%). Conclusion: Although our interaction term did not reach significance, the increased risk of infection associated with corticosteroids use was more pronounced in PLWH. However, further research with contemporary data is warranted to confirm if the risk associated with corticosteroids use remains high in PLWH with well-controlled HIV infection.

Cet article fait état des connaissances nouvelles sur lephénomène des gangs de rue découlant d’unerecension critique de la littérature scientifique sur le sujet.Cette recension se concentre sur des articles parus après 1997,soit après la publication d’une première recensionsur le sujet au Québec. En exerçant certains comparatifsentre les deux recensions, il apparaît non seulement que lesconnaissances se sont beaucoup développées sur certainsplans, mais que la manière d’aborder la complexitédu problème s’est littéralement transformée.Dans le cadre de cet article, nous traitons spécifiquement desprocessus de l’engagement et du désistement, de laviolence des gangs et des caractéristiques internes des jeunesqui s’y joignent, soit là où cette transformationest particulièrement saisissante. En terminant, nous proposonsquelques pistes de réflexion sur les incidences possibles surl’intervention auprès des jeunes qui fontl’expérience de ces groupes.

The objective of this study was to assess the effects of radiofrequency energy application on implanted pacemaker functions. Radiofrequency (RF) catheter ablation may cause pacemaker dysfunction due to electromagnetic interferences. The effects of RF on pacemaker behavior were studied in a series of 38 pacemakers, implanted 18 +/- 26 months prior to a RF procedure using either a right ventricular approach (AV node ablation, n = 35) or a left ventricular approach (left concealed accessory pathway ablation, n = 1; VT ablation, n = 2). The 38 patients (mean age 65 +/- 9 years) included 20 men and 18 women. Before energy applications, the 23 different pacemaker models were programmed to the VVI mode at the lowest available rate. The continuous surface ECG was recorded throughout the procedure. Thorough testing of the devices was performed before and after each RF delivery. Unusual pacemaker responses occurred in 20 of the 38 cases studied (53%). The impact of RF delivery was unpredictable, and variable dysfunctions were observed at different times for a given patient or could vary for a given model. Unusual pacemaker responses included pacemaker inhibition (n = 8), untoggled backup mode (n = 3), electromagnetic interference noise mode (n = 3), temporary RF-induced pacemaker tachycardia (n = 2), erratic behavior (n = 1), oversensing of RF onset and offset (n = 8), and transient loss of ventricular capture, (n = 1). Postablation, most devices automatically toggled back to full functionality. The three devices in the untoggled backup mode had to be reprogrammed to obtain normal operations. At the end of the procedure, pacing thresholds remained unchanged in all but one patient, in whom the increase in ventricular threshold was due to a nicked lead. In conclusion, implanted pacemakers frequently exhibit transient, unpredictable responses to RF energy application. Although all pacemaker functions were restored postablation, some devices had to be reset manually. The anomalies observed during the RF application argue for the simultaneous use of an external pacemaker in pacing-dependent patients.